Author:
Geiges Götz,Harms Thomas,Rodemer Gerald,Eckert Ralf,König Frank,Eichenauer Rolf,Schroder Jörg
Publisher
Springer Science and Business Media LLC
Subject
Urology,Reproductive Medicine,General Medicine
Reference27 articles.
1. Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008;102(11):1531–8.
2. Crawford ED, Tombal B, Miller K, Boccon-Gibod L, Schroder F, Shore N, et al. A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer. J Urol. 2011;186(3):889–97.
3. Ozono S, Ueda T, Hoshi S, Yamaguchi A, Maeda H, Fukuyama Y, et al. The efficacy and safety of degarelix, a GnRH antagonist: a 12-month, multicentre, randomized, maintenance dose-finding phase II study in Japanese patients with prostate cancer. Jpn J Clin Oncol. 2012;42(6):477–84.
4. Van Poppel H. LHRH agonists versus GnRH antagonists for the treatment of prostate cancer. Belgian J Med Oncol. 2010;4:18–22.
5. Thompson IM. Flare associated with LHRH-agonist therapy. Rev Urol. 2001;3 Suppl 3:S10–14.
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献